Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In t ...

Moderna's next COVID-19 vaccine has received Food and Drug Administration approval, albeit with restrictions not placed on the company's current shot. The new vaccine, called mNEXSPIKE, can be ...

mNEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration ...

Moderna said mNEXSPIKE was approved by the FDA for use in all adults ages 65 and up, as well as individuals aged 12 to 64 with at least one or more underlying risk factors.

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA ®, the Company's approved respiratory ...